Trials of diminishing relapses for diminishing returns

The Lancet Neurology

Volumn 8, Issue 10, 2009, Pages 870-871

  Coles, Alasdair ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GLATIRAMER; INTERFERON BETA SERINE;

COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRAIN; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69749101714     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70234-0     Document Type: Letter

References (3)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. Mikol D.D., Barkhof F., Chang P., et al., for the REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7 (2008) 903-914
3. O'Connor P., Filippi M., Arnason B., et al., for the BEYOND study group. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing remitting multiple sclerosis: a prospective, randomised multicentre study. Lancet Neurol (2009) available online September 2. DOI:1016.S1474-4422(09)70226-1.